The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,339K data for 617K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

98 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.EBI
Pfizer
Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.EBI
University Of Minnesota
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.EBI
Takeda Pharmaceutical
Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.EBI
Universidad Ceu San Pablo
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.EBI
Takeda Pharmaceutical
Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.EBI
University Of Lille
Discovery of a New Class of Potent MMP Inhibitors by Structure-Based Optimization of the Arylsulfonamide Scaffold.EBI
University Of Florence
Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.EBI
Florida State University
Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.EBI
Mayo Clinic
Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.EBI
Pomona College
Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.EBI
Wroclaw University Of Technology
Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.EBI
TBA
Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.EBI
Alantos Pharmaceuticals
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI
University Of Florida
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI
Johnson & Johnson Pharmaceutical Research & Development
Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI
Pfizer
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Research And Development
Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.EBI
Instituto Superior T£Cnico
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.EBI
Universit£
Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI
Wyeth Research
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.EBI
Dupont Pharmaceuticals
Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.EBI
TBA
Protease inhibitors: current status and future prospects.EBI
University Of Queensland
Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.EBI
Parke-Davis Pharmaceutical Research
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.EBI
F. Hoffmann-La Roche
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.EBI
Procter And Gamble Pharmaceuticals
Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.EBI
Procter And Gamble Pharmaceuticals
Discovery of potent, achiral matrix metalloproteinase inhibitors.EBI
Procter And Gamble Pharmaceuticals
Heterocycle-based MMP inhibitors with P2' substituents.EBI
Procter And Gamble Pharmaceuticals
Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI
Pfizer
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.EBI
Boehringer Ingelheim Pharmaceuticals
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.EBI
Instituto Superior T£Cnico
Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).EBI
Pfizer
Selective water-soluble gelatinase inhibitor prodrugs.EBI
University Of Notre Dame
Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.EBI
Pfizer
Structure and activity relationships of tartrate-based TACE inhibitors.EBI
Merck Research Laboratories
MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.EBI
Pfizer
2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI
Merck Research Laboratories
Sulfonate-Containing Thiiranes as Selective Gelatinase InhibitorsEBI
TBA
Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).EBI
Protera
Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.EBI
Merck Research Laboratories
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.EBI
Pfizer
Discovery and SAR of hydantoin TACE inhibitors.EBI
Merck Research Laboratories
The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.EBI
Schering-Plough Research Institute
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI
Pfizer
The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.EBI
Gsk Medicines Research Centre
Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group.EBI
University Of Shizuoka And Global Coe Program
Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.EBI
Wyeth Research
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.EBI
Schering-Plough Research Institute
 
Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocketEBI
TBA
 
Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2′-P3′ amide bond isostereEBI
TBA
 
Novel indolactam-based inhibitors of matrix metalloproteinasesEBI
TBA
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI
University Of Athens
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.EBI
Université
Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.EBI
North Dakota State University
Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.EBI
Università
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.EBI
Pfizer
Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.EBI
Università
Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.EBI
Aventis Pharma Deutschland
Synthesis and SAR of highly selective MMP-13 inhibitors.EBI
Wyeth Research
Identification of potent and selective MMP-13 inhibitors.EBI
Wyeth Research
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.EBI
University Of Athens
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.EBI
Chinese Academy Of Sciences
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.EBI
Pfizer
Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.EBI
Indiana University School Of Medicine
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.EBI
Bristol-Myers Squibb
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.EBI
Abbott Laboratories
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.EBI
Dupont Pharmaceuticals
Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.EBI
British Biotech Pharmaceuticals
The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.EBI
Procter And Gamble Pharmaceuticals
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.EBI
Abbott Laboratories
Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.EBI
Roche Research Center
Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.EBI
Procter And Gamble Pharmaceuticals
Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.EBI
Procter And Gamble Pharmaceuticals
Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.EBI
University Of Florida
Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.EBI
Cea
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.EBI
Abbott Laboratories
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.EBI
Abbott Laboratories
Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.EBI
Affymax Research Institute
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.EBI
Shionogi
Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.BDB
Suven Life Sciences
Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.BDB
Eli Lilly
Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.BDB
Georgetown University
Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase.BDB
Syntex Discovery Research
Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family.BDB
Novo Nordisk
Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.BDB
Fujisawa Pharmaceutical